%PDF-1.4
%
1 0 obj
<>stream
application/pdf
10.1080/17512433.2017.1322507
en
A consensus statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus
A. Avogaro
A. Giaccari
P. Fioretto
S. Genovese
F. Purrello
F. Giorgino
S. Del Prato
Taylor & Francis
Expert Review of Clinical Pharmacology, 2017. doi:10.1080/17512433.2017.1322507
Dapagliflozin
sodium-glucose co-transporter-2 inhibitor
diabetes type 2
cardiovascular disease
diabetic complications
Journal
Expert Review of Clinical Pharmacology
© 2017 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
1751-2433
1751-2441
10
7
763
772
10.1080/17512433.2017.1322507
https://doi.org/10.1080/17512433.2017.1322507
VoR
2017-06-11T08:27:05+05:30
Arbortext Advanced Print Publisher 11.0.3352/W Unicode
2020-07-13T03:00:50-07:00
2020-07-13T03:00:50-07:00
Dapagliflozin; sodium-glucose co-transporter-2 inhibitor; diabetes type 2; cardiovascular disease; diabetic complications
iText 4.2.0 by 1T3XT
uuid:ad7db769-68af-4316-b95e-4735cb09a942
uuid:4b9d0a93-7b53-441b-a6df-d3d9b5609fcb
2017-05-02truewww.tandfonline.com10.1080/17512433.2017.1322507www.tandfonline.comtrue2017-05-0210.1080/17512433.2017.1322507
endstream
endobj
4 0 obj
<>stream
xZn,+B| hpvIdaxeJl*!=ѵ|7Ed8X'O[\4q1$χo嗱gOe]5!Z-÷]6qIuF%ӽ};wyO]BLD/4wY9o#L4xM?./I"*Q]U |Ԯz\eUK= ] ˗&|ύ*TsF1$gE}`&Vi?Nm=\:|S/czgRN.
Hskyy]01+/ٿX?
kÿ9qqC\Kqw?Ht~^{ϴDMɕGhVq|ЪY;*"j&VvGU!r13@<`ݢ ]Lzd q-cEzgw]u<6ߣzG.N
[MK}f!z1o*fQ:hhGE/zwwax}-J4TS1ުS֛ ȶC]AX?y ,F?Kl.@ןlYsx
ΓK
8#7rv
^'ZTrwk
~H(?_vj\CG/MˇG͆ؕy(s;wL;NIi 8l^!^Qß?X+c>>"nq5A/j ]kl6d^mk+*PyS5la}4n]!X]0!sp,'=6W֒/%kgЄ]H f334¶"ep)<'t:f"a# iҍvgmTZ @Թ@29Fyu@\1C08SH\U[yӦ6*M:/O;TM';)h#z
[W3O͉!yͷVɃ
TW;PЄEYfЁW?FE0Y{V\a8$fvCGw>Nk.c([iad&ny@'Uyƞȧi){(o˴/?EoT.Y'p5uTZM욇MC3ƞi'j'dO%Yuehkj+'4f='x0s(]uZ~^uֱ